- Home
- AII vs ABEO Comparison
AII vs ABEO Comparison
Compare AII & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AII | ABEO |
|---|---|---|
| Founded | 2006 | 1974 |
| Country | United States | United States |
| Employees | 313 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.9M | 399.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | AII | ABEO |
|---|---|---|
| Price | $20.72 | $6.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $26.33 | $20.00 |
| AVG Volume (30 Days) | 75.0K | ★ 1.3M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.27% | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | $35.92 | $1,024.31 |
| Revenue Next Year | $17.74 | $145.42 |
| P/E Ratio | $4.12 | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $16.19 | $4.00 |
| 52 Week High | $26.36 | $7.54 |
Technical Indicators
Market Signals| Indicator | AII | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 68.10 | 50.75 |
| Support Level | $17.96 | $4.85 |
| Resistance Level | $21.21 | $7.36 |
| Average True Range (ATR) | 0.74 | 0.33 |
| MACD | 0.17 | -0.07 |
| Stochastic Oscillator | 98.29 | 34.97 |
Price Performance
Historical ComparisonAbout AII American Integrity Insurance Group Inc.
American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, North Carolina, South Carolina, and Georgia.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.